201 related articles for article (PubMed ID: 36788424)
1. Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.
Argirion I; Pfeiffer RM; Proietti C; Coghill AE; Yu KJ; Middeldorp JM; Sarathkumara YD; Hsu WL; Chien YC; Lou PJ; Wang CP; Rothman N; Lan Q; Chen CJ; Mbulaiteye SM; Jarrett RF; Glimelius I; Smedby KE; Hjalgrim H; Hildesheim A; Doolan DL; Liu Z
Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):687-696. PubMed ID: 36788424
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
[TBL] [Abstract][Full Text] [Related]
3. The Association between the Comprehensive Epstein-Barr Virus Serologic Profile and Endemic Burkitt Lymphoma.
Coghill AE; Proietti C; Liu Z; Krause L; Bethony J; Prokunina-Olsson L; Obajemu A; Nkrumah F; Biggar RJ; Bhatia K; Hildesheim A; Doolan DL; Mbulaiteye SM
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):57-62. PubMed ID: 31619404
[TBL] [Abstract][Full Text] [Related]
4. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma.
Liu Z; Jarrett RF; Hjalgrim H; Proietti C; Chang ET; Smedby KE; Yu KJ; Lake A; Troy S; McAulay KA; Pfeiffer RM; Adami HO; Glimelius B; Melbye M; Hildesheim A; Doolan DL; Coghill AE
Int J Cancer; 2020 Aug; 147(3):608-618. PubMed ID: 31618442
[TBL] [Abstract][Full Text] [Related]
6. Antibody Profiling of Pan-Cancer Viral Proteome Reveals Biomarkers for Nasopharyngeal Carcinoma Diagnosis and Prognosis.
Liang T; Chen H; Liu L; Zheng Y; Ma Z; Min L; Zhang J; Wu L; Ma J; Liu Z; Zhang Q; Luo K; Hu D; Ji T; Yu X
Mol Cell Proteomics; 2024 Mar; 23(3):100729. PubMed ID: 38309569
[TBL] [Abstract][Full Text] [Related]
7. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
9. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels.
Guo X; Li T; Li F; Xu Y; Wang H; Cheng W; Tang J; Zhou G; Chen H; Ng M; Ji M; Ge S; Xia N
Oral Oncol; 2019 Jun; 93():85-90. PubMed ID: 31109701
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.
Song L; Song M; Camargo MC; Van Duine J; Williams S; Chung Y; Kim KM; Lissowska J; Sivins A; Gao W; Karthikeyan K; Park J; Leja M; Cohen JI; LaBaer J; Qiu J; Rabkin CS
Gastric Cancer; 2021 Jul; 24(4):858-867. PubMed ID: 33661412
[TBL] [Abstract][Full Text] [Related]
11. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
[TBL] [Abstract][Full Text] [Related]
12. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.
Coghill AE; Hildesheim A
Am J Epidemiol; 2014 Oct; 180(7):687-95. PubMed ID: 25167864
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
[No Abstract] [Full Text] [Related]
15. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
17. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
18. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
20. Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.
Liao Y; Zhang JB; Lu LX; Jia YJ; Zheng MQ; Debelius JW; He YQ; Wang TM; Deng CM; Tong XT; Xue WQ; Cao LJ; Wu ZY; Yang DW; Zheng XH; Li XZ; Wu YX; Feng L; Ye W; Mu J; Jia WH
Microbiol Spectr; 2023 Feb; 11(1):e0344822. PubMed ID: 36645283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
